Two phase-I clinical trials are on-going in France, assessing pretargeted 177Lu-IMP288 (one injection) in patients with metastatic CEA-positive lung carcinoma, and fractionated injection of 90Y-IMP288 in metastatic CRC patients. This evidence concerns the gene CEACAM5 and lung carcinoma.